Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: A case report

Annals of the Academy of Medicine Singapore

Volumn 39, Issue 2, 2010, Pages 143-145

  Wu, Ziqiang ^a   Huang, Jingjing ^b   Sadda, Srinivas ^c  

^a Center for Advanced Eye Care   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Anti VEGF therapy; Pre eclampsia; Vasculogenesis

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VERTEPORFIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BREAST FEEDING; CASE REPORT; DRUG USE; EYE; EYE EXAMINATION; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; METAMORPHOSIS; MULTIPLE CYCLE TREATMENT; MYOPIA; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT COUNSELING; PHOTODYNAMIC THERAPY; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY TEST; PUERPERIUM; RETINA HEMORRHAGE; RETINA MACULA EDEMA; RETINA MACULA LUTEA; RISK BENEFIT ANALYSIS; SCAR; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; TREATMENT REFUSAL; VAGINAL DELIVERY; VISION; VISUAL ACUITY; VISUAL DISORDER;

EID: 77949505901     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-6.
2. Bennett MD, Yee W. Pegaptanib for myopic choroidal neovascularization in a young patient. Graefes Arch Clin Exp Ophthalmol 2007;245:903-5.
3. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosa A, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-23.
4. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.
5. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72.
6. Wu Z, Sadda SR. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann Acad Med Singapore 2008;37:591-3.
7. Rosen E, Rubowitz A, Ferencz JR. Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye 2009;23:1479.
8. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fl uid. Science 1983;219:983-5.
9. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor specific for vascular endothelial cells. Science 1989;246:1306-9.
10. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparinbinding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
12. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 2002;4:E2-5.
13. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004;7:193-201.
14. Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Behcecioglu H. The effect of intravitreal bevacizumab (Avastin) administration on systemic hypertension. Eye 2009;23:1714-8.
15. Demir R, Kayisli UA, Cayli S, Huppertz B. Sequential steps during vasculogenesis and angiogenesis in the very early human placenta. Placenta 2006;27:535-9.
16. Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3185-93.
17. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, et al. Vascular endothelial growth factor in ocular fl uid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
18. Kvanta A, Algvere PV, Berlin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration expresses vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996;37:1929-34.
19. Heiduschka P, Fietz H, Hofmeister S, Shultheis S, Mack AF, Peters S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-23.
20. Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol 2008;146:508-12.
21. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82.
22. Press Release from SAILOR trial to Healthcare Providers. Available at: http://www.gene.com/gene/products/information/pdf/healthcareprovider-letter.pdf. Accessed 6 July 2009.
23. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: phase III clinical trial results. Ophthalmol Clin North Am 2006;19:361-72.
24. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.